阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌的1b期试验
这项在美国10个中心开展的非随机、开放标签1b期研究,纳入52例初治晚期肾细胞癌患者,采用阿昔替尼5 mg每日两次联合帕博利珠单抗2 mg/kg每3周方案。
要点
- 阿昔替尼5 mg每日两次联合帕博利珠单抗2 mg/kg每3周方案在初治晚期肾细胞癌中可耐受
- 最常见3级及以上治疗相关不良事件为高血压(23%)、腹泻(10%)、乏力(10%)
核心结论
- 阿昔替尼联合帕博利珠单抗在初治晚期肾细胞癌患者中可耐受并显示出有前景的抗肿瘤活性。
- 联合方案是否优于VEGF通路抑制后序贯抗PD-1治疗,尚待比较阿昔替尼联合帕博利珠单抗与舒尼替尼单药的3期试验(NCT02853331)完成。
研究设计与样本
- 研究为正在进行的开放标签1b期研究,在美国10个中心开展,含剂量探索期与剂量扩展期。
- 2014年9月23日至2015年3月25日入组11例患者进入剂量探索期,2015年6月3日至2015年10月13日入组41例进入剂量扩展期,共52例初治晚期肾细胞癌患者统一分析。
- 主要终点为研究者评估的前两个周期(6周)剂量限制性毒性,用于估计最大耐受剂量和推荐2期剂量。
主要发现
- 剂量探索期11例患者6周观察期内报告3例剂量限制性毒性:1例短暂性脑缺血发作,2例因治疗相关毒性仅完成不足75%的计划阿昔替尼剂量。
- 数据截止2017年3月31日,25例(48%)患者仍在接受研究治疗。
- 3级及以上治疗相关不良事件发生于34例(65%)患者,最常见为高血压12例(23%)、腹泻5例(10%)、乏力5例(10%)、丙氨酸氨基转移酶升高4例(8%)。
- 可能与帕博利珠单抗相关的潜在免疫相关不良事件最常见为腹泻15例(29%)、丙氨酸氨基转移酶升高9例(17%)、天冬氨酸氨基转移酶升高7例(13%)、甲状腺功能减退7例(13%)、乏力6例(12%)。
关键数值与推荐
- 入组条件为年龄18岁及以上、晚期肾细胞癌(以透明细胞亚型为主)、原发肿瘤已切除、至少一个可测量病灶、ECOG体能状态0-1、高血压控制良好、无既往肾细胞癌全身治疗。
- 给药方案为阿昔替尼5 mg口服每日两次联合帕博利珠单抗2 mg/kg静脉给药每3周一次。
- 安全性在至少接受一剂阿昔替尼或帕博利珠单抗的全部患者中评估,抗肿瘤活性在接受研究治疗且基线肿瘤评估充分的患者中评估。
临床怎么用
- 该联合方案为初治晚期肾细胞癌提供了可耐受且缓解率较高的治疗选择,但需密切监测高血压、腹泻、乏力及肝酶升高等毒性。
- 潜在免疫相关不良事件(腹泻、肝酶升高、甲状腺功能减退)需按帕博利珠单抗相关毒性进行识别与管理。
- 联合方案与舒尼替尼单药的优劣尚未确定,临床决策应等待3期对照试验结果。
局限性
- 本研究为非随机、开放标签1b期试验,样本量52例,无对照组,疗效与安全性结论需3期随机试验验证。
- 数据截止2017年3月31日,随访时间有限,总生存等长期结局未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective VEGF inhibitor than others previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield antitumour activity in patients with treatment-naive advanced renal cell carcinoma. METHODS: In this ongoing, open-label, phase 1b study, which was done at ten centres in the USA, we enrolled patients aged 18 years or older who had advanced renal cell carcinoma (predominantly clear cell subtype) with their primary tumour resected, and at least one measureable lesion, Eastern Cooperative Oncology Group performance status 0-1, controlled hypertension, and no previous systemic therapy for renal cell carcinoma. Eligible patients received axitinib plus pembrolizumab in a dose-finding phase to estimate the maximum tolerated dose, and additional patients were enrolled into a dose-expansion phase to further establish safety and determine preliminary efficacy. Axitinib 5 mg was administered orally twice per day with pembrolizumab 2 mg/kg given intravenously every 3 weeks. We assessed safety in all patients who received at least one dose of axitinib or pembrolizumab; antitumour activity was assessed in all patients who received study treatment and had an adequate baseline tumour assessment. The primary endpoint was investigator-assessed dose-limiting toxicity during the first two cycles (6 weeks) to estimate the maximum tolerated dose and recommended phase 2 dose. This study is registered with ClinicalTrials.gov, number NCT02133742. FINDINGS: Between Sept 23, 2014, and March 25, 2015, we enrolled 11 patients with previously untreated advanced renal cell carcinoma to the dose-finding phase and between June 3, 2015, and Oct 13, 2015, we enrolled 41 patients to the dose-expansion phase. All 52 patients were analysed together. No unexpected toxicities were observed. Three dose-limiting toxicities were reported in the 11 patients treated during the 6-week observation period (dose-finding phase): one patient had a transient ischaemic attack and two patients were only able to complete less than 75% of the planned axitinib dose because of treatment-related toxicity. At the data cutoff date (March 31, 2017), 25 (48%) patients were still receiving study treatment. Grade 3 or worse treatment-related adverse events occurred in 34 (65%) patients; the most common included hypertension (n=12 [23%]), diarrhoea (n=5 [10%]), fatigue (n=5 [10%]), and increased alanine aminotransferase concentration (n=4 [8%]). The most common potentially immune-related adverse events (probably related to pembrolizumab) included diarrhoea (n=15 [29%]), increased alanine aminotransferase concentration (n=9 [17%]) or aspartate aminotransferase concentration (n=7 [13%]), hypothyroidism (n=7 [13%]), and fatigue (n=6 [12%]). 28 (54%) patients had treatment-related serious adverse events. At data cutoff, 38 (73%; 95% CI 59·0-84·4) patients achieved an objective response (complete or partial response). INTERPRETATION: The treatment combination of axitinib plus pembrolizumab is tolerable and shows promising antitumour activity in patients with treatment-naive advanced renal cell carcinoma. Whether or not the combination works better than a sequence of VEGF pathway inhibition followed by an anti-PD-1 therapy awaits the completion of a phase 3 trial comparing axitinib plus pembrolizumab with sunitinib monotherapy (NCT02853331). FUNDING: Pfizer Inc.
引用
- Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018. PMID: 29439857. doi:10.1016/S1470-2045(18)30081-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。